

# **Company Presentation**

August 2024





# **Confidentiality and Disclaimer**

This confidential presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the "proposed business combination") between Euda Health Limited ("EUDA") and 8i Acquisition 2 Corp ("8i" or the "SPAC") and related transactions and for no other purpose. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute financial investment, tax or legal advice. To the fullest extent permitted by law in no circumstances will EUDA, 8i or any of their respective subsidiaries, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this presentation, its contents, its omissions, errors, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. No representations or warranties, express or implied, is or will be given by EUDA, 8i or any of their respective affiliates, directors, officers, employees or advisors or any other person as to the accuracy, completeness, reasonableness of statements, estimates, targets, projections, assumptions or judgments in this presentation, or in any other written, oral or other communications transmitted otherwise made available to any part in the course of its evaluation of a possible transaction, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. Industry and market data used in this presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither EUDA nor 8i has independently verified the data obtained f

The information in this presentation is highly confidential. The distribution of this presentation by an authorized recipient to any other person is unauthorized. Any photocopying, disclosure, reproduction or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. The recipient of this presentation shall keep this presentation and its contents confidential, shall not use this presentation and its contents for any purpose other than as expressly authorized by EUDA and 8i and shall be required to return or destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements. This presentation contains trademarks, service marks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.



# Forward-looking Statements

This document includes certain statements, estimates, targets, forward-looking statements, and projections (collectively, "forward-looking statements") that reflect assumptions made by EUDA concerning anticipated future performance of EUDA and its industry. Such forward-looking statements are based on significant assumptions and subjective judgments concerning anticipated results, which are inherently subject to risks, variability, and contingencies, many of which are beyond EUDA's control. Factors that could cause actual results to differ from these forward-looking statement include, but are not limited to, general economic conditions, the availability and terms of financing, the effects and uncertainties created by the ongoing COVID-19 pandemic, EUDA's limited operating history, changes in regulatory requirements and governmental incentives, competition, and other risks and uncertainties associated with EUDA's research and development activities and commercial production and sales. Such forwardlooking statements may be identified by the use of words like "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "will", "should", "seek" and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. EUDA shall not undertake any duty to update these forward-looking statements, or the other information contained in this presentation. EUDA do not make any representation or warranty, express or implied, as to the accuracy or completeness of this document or any other information (whether written or oral) that has been or will be provided to you. Nothing contained herein or in any other oral or written information provided to you is, nor shall be relied upon as, a promise or representation of any kind by EUDA. Without limitation of the foregoing, EUDA expressly disclaims any representation regarding any projections concerning future operating results or any other forward-looking statement contained herein or that otherwise has been or will be provided to you. EUDA shall not be liable to you or any prospective investor or any other person for any information contained herein or that otherwise has been or will be provided to you, or any action heretofore or hereafter taken or omitted to be taken, in connection with this potential transaction. These forward-looking statements also involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted in connection with any proposed business combination; (2) the inability to complete any business combination; (3) delays in obtaining, or inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete any business combination; (4) the risk that any proposed business combination disrupts current plans and operations; (5) the inability to recognize the anticipated benefits or any propose business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and partners and retain key employees; (6) costs related to any proposed business combination; (7) changes in the applicable laws or regulations; (8) the possibility that EUDA or the Combined Company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) other risks and uncertainties separately provided to the recipient and indicated from time to time described in 8i"s filings and future filings by EUDA, 8i and the Combined Company with the U.S. Securities and Exchange Commission. EUDA and 8i caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. EUDA and 8i undertake no obligation to and accepts no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

No Offer Or Solicitation: This communication does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with the Proposed Investment or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful.

**Private Placement**: The securities to which this presentation relates have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction. This presentation relates to securities that EUDA would intend to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense.



# **Forward-looking Statements**

Use of Projections: This presentation contains projected financial information with respect to EUDA. Such projected financial information contains forward-looking information and is for illustration purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecasts information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in the presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved.

Financial Information; Non-GAAP Financial Terms: The financial information and data contained in this presentation is unaudited and does not conform to Regulation S-X promulgated by the Securities and Exchange Commission ("SEC"). Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement or registration statement or other report or document to be filed by 8i with the SEC. Furthermore, some of the projected financial information and data contained in this presentation, such as adjusted EBITDA (and related measures), has not been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). 8i and EUDA believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to EUDA' financial condition and results of operations. EUDA' management uses these non-GAAP measures for trends analyses and for budgeting and planning purposes. 8i and EUDA believe that use of these non-GAAP measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing EUDA's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of EUDA does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in EUDA' financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. You should review EUDA's audited financial statements, which will be presented in 8i's proxy statement to be filed with the SEC, and not rely on

Trademarks: This presentation contains trademarks, trade names and copyrights of EUDA, 8i and other companies, which are the property of their respective owners.

Additional Information and Where to Find it: This document relates to a proposed transaction between 8i and EUDA. 8i intends to file a proxy statement which will be sent to all 8i shareholders. 8i also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of 8i and EUDA are urged to read the proxy statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by 8i through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by 8i may be obtained free of charge from 8i's website at www.8iac.com or by written request to 8i at 6 Eu Tong Sen Street, #08-13 Singapore 059817.

Participants in Solicitation: 8i and EUDA and their respective directors and officers may be deemed to be participants in the solicitation of proxies from 8i's shareholders in connection with the proposed transaction. Information about 8i's directors and executive officers and their ownership of 8i's securities is set forth in 8i's filings with the SEC, including 8i's Registration Statement on Form S-1, which was filed with the SEC on November 9, 2021. To the extent that holdings of 8i's securities have changed since the amounts printed on 8i's Registration Statement on Form S-1, such changes will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of these persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.



# **EUDA Health – Reimagining the Future of Modern Health**

EUDA Health Limited is an innovative health technology enterprise spearheading a digital healthcare ecosystem throughout Southeast Asia. Our mission is to transform the health and wellness landscape by advancing non-invasive treatments and enabling holistic healthcare access through cutting-edge technology integration. Our strategic expansion into the Malaysian market, driven by the acquisition of CK Health Plus Sdn Bhd — a frontrunner in comprehensive wellness solutions — signifies a major leap in bolstering our regional footprint and service portfolio.

## **Our Business Model**




# Delivering Exceptional Medical Assistance & Evacuation

- Teleconsultations, health screenings, and specialist referrals
- Emergency care and evacuation (domestic)
- Medical concierge services
- Online health management and telehealth consultations
- Corporate health and insurance management services



# Empowering Wellness with Consumer Products

- Comprehensive range of consumer wellness products that promote holistic wellness
- Enhance your well-being and self-care routine
- Upgrade your lifestyle with our healthy, non-invasive offerings



Transforming Healthcare through an Integrated AI Platform

- Personalized and affordable virtual healthcare services
- Improved patient experience and clinical outcomes
- Utilize advanced technology for efficient and convenient healthcare
- Ideal for individuals seeking convenient and accessible healthcare solutions


















# **Vast Market Potential**







1.2 Billion by 2025

People aged **60 and older** in **developing Asia** and the Pacific



## **Healthcare Spending Surge**

 By 2030, Asia-Pacific, growing fastest in healthcare spending, will account for over 20% of global expenditures, indicating access, cost, and quality challenges.

#### **Proactive Health Investment**

• Consumers demand better health experiences, taking control of their health and investing in wellness.

## **Integrated Care Demand**

 According to our 2023 survey, consumers increasingly prefer integrated care pathways, particularly for chronic conditions.

## Al Acceptance in Healthcare

 By 2023, over 50% of Asia-Pacific respondents will welcome AI in healthcare delivery, especially for preventive care and minor conditions, a rise from 2019's 22%.

### **Increasing Trust in Digital Health**

 Nearly 70% of consumers in India, Indonesia, and China trust digital health and technology companies with their healthcare needs.



# **Innovative Technology Solutions**



Convenient & timely access



Better outcomes & long-term cost savings



Better care coordination

## **Artificial Intelligence**

EUDA uses AI for healthcare analytics, early health outcome prediction, and personalized treatment advice.





0






## Machine Learning

EUDA uses machine learning for predictive modeling, risk stratification, and personalized healthcare.









# **Big Data Analytics**

EUDA analyzes large healthcare data sets, identifying trends and insights to improve patient care.



## **Blockchain Technology**

EUDA uses blockchain for secure health record transmission and payment processing, ensuring data integrity and privacy.

# **Cloud-based Decision Support System**

EUDA's system includes proprietary algorithms for digital triage, smart service matching, remote patient management, and Al-based treatment advice.



# **Experienced Leadership Team**

EUDA's management team boasts a robust blend of healthcare, technology, and business expertise. With a proven track record in scaling digital health solutions and driving innovation, the leadership is adept at navigating the complexities of the healthcare sector and steering the company towards sustained growth.









**Dr Kelvin Chen** 

Founder & Chief Executive Officer

Dr Kelvin Chen has amassed over 15 years of experience in executive management and in the healthcare sector. He was the former SVP of Healthway Medical.

He holds a Doctorate in Business Administration from the University of South Australia and graduated from University of Greenwich, with a Bachelor's Degree in Computer Science.

William Tan

Chief Financial Officer

Mr. Tan has over 20 years of experience in accounting and finance. From 2012 to 2015, Mr. Tan served as a non-executive independent director of China Sky Chemical Fibre Co., Ltd. Currently he is a non-executive independent director of Unusual Limited since 2017. He served as Financial Controller of Nixvue Systems Pte Ltd (2001-2005), Group Financial Controller of Unidux Electronics Ltd (2005-2007), CFO of SNF Corporation Ltd (2007), and Sinostar PEC Holdings Ltd (2008-2023).

Mr. Tan is a non-practicing member of the Institute of Singapore Chartered Accountants and a fellow of the Association of Certified Chartered Accountants (UK).

**Yusoff Bin Yacob** 

Security Director

Mr. Yusoff is a former Lieutenant Colonel (NS) with SCDF holding the appointment of Battalion Commander and has more than 30 years of handson experience in security operations, risk management, and crisis response,

He is skilled in leading security teams, conducting security assessments, and executing strategies to safeguard assets, mitigate risks, and ensure the safety of security personnel.

**Anthony Lim** 

Legal & MCST Director

Mr. Lim possess an LLB (Hons), Degree in Law, from University of London and started his career in Property Management in 1995 and has since managed more than 100 projects including commercial, residential mix-developments and industrial properties. He also possess a certificate in Managing Agent Practice from renowned SISV-APFM.

Joanne Khoo


Human Resources

Ms. Koo has more than 20 years experience in process management, human resource development and management.

She leads corporate recruitment, drives training initiatives, and possesses a proven sterling track record in employee relations, performance management, training, development, and policy implementation for various companies under her charge.







# Strategic Acquisition and Long-term Expansion





## **Strategic Acquisition with CK Health**



#### **Complementary Expertise**

EUDA's tech skills and CK
Health's industry know-how form
a partnership ready for innovation
in the health & wellness sector.



#### **Market Expansion**

The acquisition enables EUDA's entry into Malaysia, boosting regional presence and growth.



#### **Diversification of Product Portfolio**

Integrating CK Health's wellness products expands EUDA's offerings, catering to diverse health needs.



#### **Enhanced Distribution Channels**

CK Health's network allows EUDA to reach a broader audience and penetrate the market effectively.



**Confinement Centers** 



**Beauty Saloon** 



**Spa Centers** 



**Hair Saloon Centers** 



Long Term Expansion Plan - Licensee & Partnership

# **Rich Product Offering**



# **Daily Wear Products**





Hydrogen Cellular Therapy

# **Bioenergy Products**







# **Nutritional Supplement Drinks**



Light Resonance Therapy

Graphene Infused Thermal Matrix

FIR Dermal Radiance

Quantum
BioEnergy Cabin
(Freq Wave Tech)











## Mitigating Inflation

With inflation remaining higher and more volatile in 2024, equities can protect your portfolio.

## **Equities Outlook**

Equities, which rose in 2023, are expected to climb further in 2024, driven by trends like AI and weightloss drugs.

#### **Balanced Portfolio**

A balanced investment portfolio is essential for managing risk.



## **Emerging Markets**

Southeast Asia (Singapore, Malaysia, Philippines, Thailand, Indonesia) shows strong growth potential.

#### **Credit Market Stress**

Despite tighter credit stressing sectors like commercial real estate and leveraged loans, a 2024 recession is unlikely, and stressed areas may offer opportunities.



# Strategic Investment Insights: Nasdaq and New York Stock Exchange

- Equities have defied expectations from 2021 through May 2024, showing significant growth despite rising interest rates.
- Despite interest rates climbing from 3.25% in 2020 to 8.5% in 2024, equity markets have thrived. This upward trend is expected to continue, especially with the anticipated reduction in the U.S. Federal Reserve's prime interest rate in 2024.
- The recommended investment sectors are poised for growth, providing robust opportunities for a diversified investment portfolio.

# ✓ Index Performance

- S&P 500:
  - January 2021 3,756.07; May 2024 5,277.51 (40% increase)
- Nasdaq:
  - January 2021 12,888.28; May 2024 16,735.02 (30% increase)
- Dow Jones:
  - January 2021 30,606.48; May 2024 38,686.32 (26% increase)



## **Recommended Investment Sectors**

#### 1. Healthcare

Services promoting healthier lifestyles, senior living solutions, and life-prolonging products.



Innovations embedding AI across various business operations.

#### 3. Real Estate

Services integrating residential purchases with related offerings.


#### 4. Electric Vehicles

Solutions addressing global warming and reducing carbon emissions.

## 5. Green/Solar Energy

Initiatives for self-sufficiency through natural resource utilization.







# THANK YOU

